Proteomics efforts for hepatocellular carcinoma drug development

Abstract

Hepatocellular carcinoma (HCC) is a malignant tumor associated with high global incidence and mortality rates. Proteomics, as a platform technology of cellular protein expression, modification, and interaction, has provided innovative perspectives on early diagnosis, treatment, and targeted drug development for HCC. This review summarizes recent progress in proteomics for advancing HCC biomarker discovery, drug target identification, and understanding drug action mechanisms. Proteomic technologies, including mass spectrometry for specific protein signatures identification, protein microarrays for high-throughput analysis, and bioinformatics for data interpretation, have profoundly promoted the identification of liver cancer-specific biomarkers. These advancements not only facilitate early diagnosis but also improve prognostic assessment. Proteomics is pivotal in expediting the discovery and development of new drugs, providing more effective and personalized treatment options for HCC patients. This review offers a comprehensive overview of the applications of proteomics in anti-HCC drug research, serving as a reference to further advance the development of HCC research and treatment domains.

Keywords

Hepatocellular carcinoma / Proteomics / Biomarkers / Anti-hepatocellular carcinoma drugs / Personalized treatment

References

[1] Ganesan P, Kulik LM. Hepatocellular carcinoma: New developments. Clin Liver Dis, 2023, 27(1): 85-102

[2] Global cancer burden growing amidst mounting need for services. Saudi Med J, 2024, 45(3): 326-327

[3] Li C, et al. Global prediction of primary liver cancer incidences and mortality in 2040. J Hepatol, 2023, 78(4): e144-e146

[4] Wang C, et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature, 2019, 574: 268-272

[5] Cabibbo G, et al. Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice. J Hepatol, 2024, 80: 957-966

[6] Llovet JM, et al. Hepatocellular carcinoma Nat Rev Dis Primers, 2016, 2: 16018

[7] Finn RS, et al. Outcomes of sequential treatment with sorafenib and regorafenib for HCC: a post-hoc analysis of the phase III RESORCE trial. J Hepatol, 2018, 69(3): 353-358

[8] Chen R, et al. SpiDe-Sr: blind super-resolution network for precise cell segmentation and clustering in spatial proteomics imaging. Nature Commun, 2024, 15(1): 2708

[9] Wang Q, et al. The mouse multi-organ proteome from infancy to adulthood. Nat Commun, 2024, 15(1): 5752

[10] Deng S, et al. Quantitative proteomics and metabolomics of culture medium from single human embryo reveal embryo quality-related multiomics biomarkers. Anal Chem, 2024, 96(29): 11832-11844

[11] Ladarola P, et al. Mass Spectrometric Proteomics 20. Int J Mol Sci, 2024, 25(5): 2960-2961

[12] Alvarez-Castelao B, et al. Nascent proteome labeling in vivo. Nat Biotechnol, 2017, 35: 1196-1201

[13] Ma YS, et al. Proteogenomic characterization and comprehensive integrative genomic analysis of human colorectal cancer liver metastasis. Mol Cancer, 2018, 17(1): 139

[14] Karjalainen MK, et al. Quantitative proteomics of protein–nucleosome interactions. Nature, 2024, 628: 130-138

[15] Xie H, Ding X. The intriguing landscape of single-cell protein analysis. Adv Sci, 2022, 9(12):

[16] Xu L, et al. Multiplex protein profiling by low-signal-loss single-cell western blotting with fluorescent-quenching aptamers. Anal Chem, 2023, 95(30): 11399-11409

[17] Tian S, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature, 2019, 567(7748): 261-265

[18] Petralia F, et al. Pan-cancer proteogenomics characterization of tumor immunity. Cell, 2024, 187: 1255-1277

[19] Xie H, et al. Photosensitive hydrogel with temperature-controlled reversible nano-apertures for single-cell protein analysis. Adv Sci, 2024, 11(19): e2308569

[20] Broyde J, et al. Oncoprotein-specific molecular interaction maps (SigMaps) for cancer network analyses. Nat Biotechnol, 2021, 39(2): 215-224

[21] Wang Y-W, et al. Post-translational modifications and immune responses in liver cancer. Front Immunol, 2023, 14: 1230465-1230471

[22] Lupberger J, et al. Combined analysis of metabolomes, proteomes, and transcriptomes of hepatitis C virus–infected cells and liver to identify pathways associated with disease development. Gastroenterology, 2019, 157(2): 537-551

[23] Ji S, et al. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology. Sci Transl Med, 2023, 15: eadg3358-eadg3372

[24] Chen H, et al. Proteomics: A new dimension to decode small cell lung cancer. Cell, 2024, 187(1): 14-16

[25] Jiang Y, He FC. Proteomic-driven precision medicine research in hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi, 2022, 30(8): 797-802

[26] Zhang T, et al. Progress and applications of mass cytometry in sketching immune landscapes. Clin Transl Med, 2020, 10(6): e206

[27] Liu X, et al. A comparison framework and guideline of clustering methods for mass cytometry data. Genome Biol, 2019, 20(1): 297

[28] Meng H, et al. A mass-ratiometry-based CD45 barcoding method for mass cytometry detection. SLAS Technol, 2019, 24(4): 408-419

[29] Zhang B, et al. Proteogenomic characterization of human colon and rectal cancer. Nature, 2014, 513(7518): 382-387

[30] He J, et al. Profiling extracellular vesicle surface proteins with 10 µL peripheral plasma within 4 h. J Extracell Vesicles, 2023, 12(9): e12364

[31] Yu Y, et al. Aptamer probes labeled with lanthanide-doped carbon nanodots permit dual-modal fluorescence and mass cytometric imaging. Adv Sci, 2021, 8(24): e2102812

[32] Yu Y, et al. Metal-labeled aptamers as novel nanoprobes for imaging mass cytometry analysis. Anal Chem, 2020, 92(9): 6312-6320

[33] Zhai C, et al. Precise identification and profiling of surface proteins of ultra rare tumor specific extracellular vesicle with dynamic quantitative plasmonic imaging. ACS Nano, 2023, 17(17): 16656-16667

[34] Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature, 2003, 422(6928): 198-207

[35] Yates JR, et al. Proteomics by mass spectrometry: approaches, advances, and applications. Annu Rev Biomed Eng, 2009, 11: 49-79

[36] Dang J, et al. New structure mass tag based on Zr-NMOF for multiparameter and sensitive single-cell interrogating in mass cytometry. Adv Mater, 2021, 33(35): e2008297

[37] Zhang S, et al. Boronic acid-rich lanthanide metal-organic frameworks enable deep proteomics with ultratrace biological samples. Adv Mater. 2024;36:2401559–72.

[38] Abdulla A, et al. Integrated microfluidic single-cell immunoblotting chip enables high-throughput isolation, enrichment and direct protein analysis of circulating tumor cells. Microsyst Nanoeng, 2022, 8: 13

[39] Wang L, et al. Sickle-like inertial microfluidic system for online rare cell separation and tandem label-free quantitative proteomics (Orcs-Proteomics). Anal Chem, 2022, 94(15): 6026-6035

[40] Zhang S, et al. Superparamagnetic composite nanobeads anchored with molecular glues for ultrasensitive label-free proteomics. Angew Chem Int Ed, 2023, 62(45): e202309806

[41] Liu X, et al. A hashing-based framework for enhancing cluster delineation of high-dimensional single-cell profiles. Phenomics, 2022, 2(5): 323-335

[42] Li Y, et al. Platinum-chimeric carrier cells for ultratrace cell analysis in mass cytometry. Anal Chem, 2023, 95(40): 14998-15007

[43] Feng D, et al. Simplified ARCHITECT microfluidic chip through a dual-flip strategy enables stable and versatile tumoroid formation combined with label-free quantitative proteomic analysis. Biofabrication, 2021, 13(3): 035024

[44] Zhang T, et al. A photoclick hydrogel for enhanced single-cell immunoblotting. Adv Funct Mater, 2020, 1002: 1910739

[45] Zhu H, et al. Global analysis of protein activities using proteome chips. Science, 2001, 293(5537): 2101-2105

[46] El-Khateeb E, et al. Proteomic quantification of changes in abundance of drug-metabolizing enzymes and drug transporters in human liver cirrhosis: Different methods, similar outcomes. Drug Metab Dispos, 2021, 49(8): 610-618

[47] Cusick ME, et al. Literature-curated protein interaction datasets. Nat Methods, 2009, 6(1): 39-46

[48] Yi X, et al. Proteome landscapes of human hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Mol Cell Proteomics, 2023, 22(8): 100604

[49] Huang PS, et al. Evaluation and application of drug resistance by biomarkers in the clinical treatment of liver cancer. Cells, 2023, 12(6): 869

[50] Shen EY, et al. The role of mass spectrometry in hepatocellular carcinoma biomarker discovery. Metabolites, 2023, 13(10): 1059

[51] He J, et al. Codetection of proteins and RNAs on extracellular vesicles for Pancreatic cancer early diagnosis. Anal Chem, 2024, 96(17): 6618-6627

[52] Xu M, et al. In-depth serum proteomics reveals the trajectory of hallmarks of cancer in hepatitis B virus-related liver diseases. Mol Cell Proteomics, 2023, 22(7):

[53] Xing X, et al. Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma. Nat Commun, 2023, 14(1): 8392

[54] Jia J, et al. Serine protease inhibitor kazal type 1, a potential biomarker for the early detection, targeting, and prediction of response to immune checkpoint blockade therapies in hepatocellular carcinoma. Front Immunol, 2022, 13

[55] Liu K, et al. Ultrasensitive proteomics of trace cardiac tissues with anchor-nanoparticles. Anal Chem, 2024, 96(23): 9460-9467

[56] Naboulsi W, et al. Quantitative tissue proteomics analysis reveals versican as potential biomarker for early-stage hepatocellular carcinoma. J Proteome Res, 2016, 15(1): 38-47

[57] Kohansal-Nodehi M, et al. Discovery of a haptoglobin glycopeptides biomarker panel for early diagnosis of hepatocellular carcinoma. Front Oncol, 2023, 13: 1213898

[58] Li D, et al. Glycoproteomic analysis of urinary extracellular vesicles for biomarkers of hepatocellular carcinoma. Molecules, 2023, 28(3): 1293

[59] Gao Q, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell, 2019, 179(5): 1240

[60] Wang W, et al. Identifies microtubule-binding protein CSPP1 as a novel cancer biomarker associated with ferroptosis and tumor microenvironment. Comput Struct Biotechnol J, 2022, 20: 3322-3335

[61] Liu L, et al. AARS2 as a novel biomarker for prognosis and its molecular characterization in pan-cancer. Cancer Med, 2023, 12(23): 21531-21544

[62] Wu KJ, et al. Phosphorylation of UHRF2 affects malignant phenotypes of HCC and HBV replication by blocking DHX9 ubiquitylation. Cell Death Discov, 2023, 9(1): 27

[63] Guo ZY, et al. RNF149 promotes HCC progression through its E3 ubiquitin ligase activity. Cancers, 2023, 15(21): 5203-5221

[64] Wei H, et al. Long non-coding RNA PAARH promotes hepatocellular carcinoma progression and angiogenesis via upregulating HOTTIP and activating HIF-1α/VEGF signaling. Cell Death Dis, 2022, 13(2): 102

[65] Wang J, et al. N6-methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells' properties and lenvatinib resistance through WNT/β-catenin and hippo signaling pathways. Gastroenterology, 2023, 164(6): 990-1005

[66] Tang Z, et al. Demethylation at enhancer upregulates MCM2 and NUP37 expression predicting poor survival in hepatocellular carcinoma patients. J Transl Med, 2022, 20(1): 49

[67] Han T, et al. Downregulation of MUC15 by miR-183–5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis. Cell Death Dis, 2022, 13(3): 200

[68] Fujita M, et al. Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets. Nat Commun, 2022, 13(1): 6481

[69] Peng JM, et al. CAMK2N1 suppresses hepatoma growth through inhibiting E2F1-mediated cell-cycle signaling. Cancer Lett, 2021, 497: 66-76

[70] Chan G, et al. Oncogenic PKA signaling increases cMYC protein expression through multiple targetable mechanisms. eLife, 2023, 12: e69521-e69547

[71] Chibaya L, et al. Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis. P Natl Acad Sci USA, 2021, 118(9): e2101572118

[72] Ayesha M, et al. MiR-4521 plays a tumor repressive role in growth and metastasis of hepatocarcinoma cells by suppressing phosphorylation of FAK/AKT pathway via targeting FAM129A. J Adv Res, 2022, 36: 147-161

[73] Lepore A, et al. Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth. Hepatology, 2021, 74(5): 2561-2579

[74] Zhang T, et al. HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET. J Exp Clin Cancer Res, 2022, 41(1): 275

[75] Li HR, et al. RIPK4 Suppresses the Invasion and Metastasis of Hepatocellular Carcinoma by Inhibiting the Phosphorylation of STAT3. Front Mol Biosci, 2021, 8

[76] Cheng F, et al. HBx promotes hepatocarcinogenesis by enhancing phosphorylation and blocking ubiquitinylation of UHRF2. Hepatol Int, 2021, 15(3): 707-719

[77] Lin X-T, et al. Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylationdependent GAPDH ubiquitination in male transgenic mice. Cell Rep, 2023, 42(7): 112812-112834

[78] Wang S, et al. Loss of hepatic FTCD promotes lipid accumulation and hepatocarcinogenesis by upregulating PPARγ and SREBP2. JHEP Rep, 2023, 5(10): 100843-100859

[79] Yang Y, et al. Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A⁺ myeloid cells to promote liver cancer progression. Gut. 2024. https://doi.org/10.1136/gutjnl-2024-332429.

[80] Takeba Y, et al. Identification of interleukin-16 production on tumor aggravation in hepatocellular carcinoma by a proteomics approach. Tumour Biol, 2021, 43(1): 309-325

[81] Hu Z, et al. Exosome-derived circCCAR1 promotes CD8⁺ T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. Mol Cancer, 2023, 22(1): 55

[82] Yuan KF, et al. Long noncoding RNA TLNC1 promotes the growth and metastasis of liver cancer via inhibition of p53 signaling. Mol Cancer, 2022, 21(1): 105

[83] Wang LN, et al. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis. J Hepatol, 2023, 79(5): 1185-1200

[84] Li Z, et al. Gain of LINC00624 enhances liver cancer progression by disrupting the histone deacetylase 6/tripartite motif containing 28/zinc finger protein 354C corepressor complex. Hepatology, 2021, 73(5): 1764-1782

[85] Du DY, et al. RNA binding motif protein 45-mediated phosphorylation enhances protein stability of ASCT2 to promote hepatocellular carcinoma progression. Oncogene, 2023, 42(42): 3127-3141

[86] Konopa A, et al. LPA receptor 1 (LPAR1) is a novel interaction partner of Filamin A that promotes Filamin A phosphorylation, MRTF-A transcriptional activity and oncogene-induced senescence. Oncogenesis, 2022, 11: 69-80

[87] Carpino G, et al. Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma. J Hepatol, 2021, 75(6): 1377-1386

[88] Tian W, et al. Identification of PPT1 as a lysosomal core gene with prognostic value in hepatocellular carcinoma. Biosci Rep, 2023, 43(5): BSR20230067

[89] Wang J, et al. Novel compound ZCJ14, a gefitinib analog, exhibited prominent anti-cancer effect among several cancer cell lines. Life Sci, 2022, 307: 120875

[90] Wang J, et al. Diagnostic and prognostic value of protein post-translational modifications in hepatocellular carcinoma. J Clin Transl Hepatol, 2023, 11(5): 1192-1200

[91] Jiang Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature, 2019, 567(7747): 257-261

[92] Chen D, et al. PPM1G promotes the progression of hepatocellular carcinoma via phosphorylation regulation of alternative splicing protein SRSF3. Cell Death Dis, 2021, 12(8): 722

[93] Wang BF, et al. Saikosaponin-d increases radiation-induced apoptosis of hepatoma cells by promoting autophagy via inhibiting mTOR phosphorylation. Int J Med Sci, 2021, 18(6): 1465-1473

[94] Xu X, et al. Phosphorylation of NF-κBp65 drives inflammation-mediated hepatocellular carcinogenesis and is a novel therapeutic target. J Exp Clin Cancer Res, 2021, 40: 253-269

[95] Jiang C, et al. Interplay between SUMO1-related SUMOylation and phosphorylation of p65 promotes hepatocellular carcinoma progression. Biochim Biophys Acta Mol Cell Res, 2024, 1871(1): 119595

[96] Sun C, et al. Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC. Cancer Lett, 2022, 526: 180-192

[97] Zhang TT, et al. Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma. Clin Transl Med, 2022, 12(5): e852

[98] Yuan Y, et al. H2A.Z acetylation by lincZNF337-AS1 via KAT5 implicated in the transcriptional misregulation in cancer signaling pathway in hepatocellular carcinoma. Cell Death Dis, 2021, 12(6): 609

[99] Gao F, et al. TSP50 promotes the Warburg effect and hepatocyte proliferation via regulating PKM2 acetylation. Cell Death Dis, 2021, 12(6): 517

[100] Yang WQ, et al. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Sci Transl Med, 2021, 13(588): eaaz6804

[101] Yang Z, et al. Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma. Nat Metab, 2023, 5(1): 61-79

[102] Bi L, et al. HDAC11 regulates glycolysis through the LKB1/AMPK signaling pathway to maintain hepatocellular carcinoma stemness. Cancer Res, 2021, 81(8): 2015-2028

[103] Jin J, et al. SIRT3-dependent delactylation of cyclin E2 prevents hepatocellular carcinoma growth. EMBO Rep, 2023, 24(5): e56052

[104] Pan L, et al. Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacol Res, 2022, 181: 106270

[105] Gao J, et al. Deficiency of betaine-homocysteine methyltransferase activates glucose-6-phosphate dehydrogenase (G6PD) by decreasing arginine methylation of G6PD in hepatocellular carcinogenesis. Sci China Life Sci. 2024;https://doi.org/10.1007/s11427-023-2481-3.

[106] Ortiz-Barahona V, et al. Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer. Mol Cancer, 2023, 22(1): 83

[107] Ji F, et al. Integrative proteomics reveals the role of E3 ubiquitin ligase SYVN1 in hepatocellular carcinoma metastasis. Cancer Commun, 2021, 41(10): 1007-1023

[108] Li H, et al. UBE2O reduces the effectiveness of interferon-α via degradation of IFIT3 in hepatocellular carcinoma. Cell Death Dis, 2023, 14(12): 854

[109] Li P, et al. CircMRPS35 promotes malignant progression and cisplatin resistance in hepatocellular carcinoma. Mol Ther, 2022, 30(1): 431-447

[110] Tey SK, et al. Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma. J Hepatol, 2022, 76(4): 883-895

[111] Wong TLM, et al. Protein tyrosine kinase 7 (PTK7) promotes metastasis in hepatocellular carcinoma via SOX9 regulation and TGF-β signaling. Cell Mol Gastroenterol Hepatol, 2023, 15(1): 13-37

[112] Qu M, et al. Circadian regulator BMAL1::CLOCK promotes cell proliferation in hepatocellular carcinoma by controlling apoptosis and cell cycle. Proc Natl Acad Sci U S A, 2023, 120(2): e2214829120

[113] Arechederra M, et al. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol, 2021, 74(4): 893-906

[114] Ge Z, et al. TIGIT and PD1 Co-blockade restores ex vivo functions of human tumor-infiltrating CD8⁺ T cells in hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol, 2021, 12(2): 443-464

[115] Wang S, et al. Comprehensive kinomic study via a chemical proteomic approach reveals kinome reprogramming in hepatocellular carcinoma tissues. Proteomics, 2022, 22(4): e2100141

[116] Li Y, et al. Deep phenotyping of T cell populations under long-term treatment of tacrolimus and rapamycin in patients receiving renal transplantations by mass cytometry. Clin Transl Med, 2021, 11(11): e629

[117] Zecha J, et al. Decrypting drug actions and protein modifications by dose- and time-resolved proteomics. Science, 2023, 380(6640): 93-101

[118] Gong Y, et al. Smad3 C-terminal phosphorylation site mutation attenuates the hepatoprotective effect of salvianolic acid B against hepatocarcinogenesis. Food Chem Toxicol, 2021, 147: 111912-111924

[119] Guo YS, et al. 17β-Estradiol promotes apoptosis of HepG2 cells caused by oxidative stress by increasing Foxo3a phosphorylation. Front Pharmacol, 2021, 12

[120] Liu Z, et al. Identification of targets of JS‑K against HBV‑positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics. Sci Rep, 2021, 11: 10381-10391

[121] Xue Z, et al. Investigating the effect of Icaritin on hepatocellular carcinoma based on network pharmacology. Front Pharmacol, 2023, 14: 1208495

[122] Li Z, Bao H. Comparative transcriptome and proteome analysis explores the antitumor key regulators of ergosterone in H22 tumor-bearing mice. Eur J Pharmacol, 2023, 953

[123] Hao BB, et al. Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations. Acta Pharmacol Sin, 2024, 45(6): 1305-1315

[124] Pan Z, et al. Role of NAT10-mediated ac4C-modified HSP90AA1 RNA acetylation in ER stress-mediated metastasis and lenvatinib resistance in hepatocellular carcinoma. Cell Death Discov, 2023, 9: 56

[125] Hsu W-C, et al. Platycodin D reverses histone deacetylase inhibitor resistance in hepatocellular carcinoma cells by repressing ERK1/2-mediated cofilin-1 phosphorylation. Phytomedicine, 2021, 82: 153442-153453

[126] Chu H, et al. Quantitative proteomics identifies FOLR1 to drive sorafenib resistance via activating autophagy in hepatocellular carcinoma cells. Carcinogenesis, 2021, 42(5): 753-761

[127] Lauer SM, et al. Recruitment of BAG2 to DNAJ-PKAc scaffolds promotes cell survival and resistance to drug-induced apoptosis in fibrolamellar carcinoma. Cell Rep, 2023, 43: 113678-113712

[128] Han WY, et al. WDR4/TRIM28 is a novel molecular target linked to lenvatinib resistance that helps retain the stem characteristics in hepatocellular carcinomas. Cancer Lett, 2023, 568: 216259-216272

[129] Wu C, et al. AKR1C3-dependent lipid droplet formation confers hepatocellular carcinoma cell adaptability to targeted therapy. Theranostics, 2022, 12(18): 7681-7698

[130] Abushawish KYI, et al. Multi-omics analysis revealed a significant alteration of critical metabolic pathways due to sorafenib-resistance in Hep3B cell lines. Int J Mol Sci, 2022, 23(19): 11975

[131] Haberkorn B, et al. Cancer-type organic anion transporting polypeptide 1B3 (Ct-OATP1B3) is localized in lysosomes and mediates resistance against kinase inhibitors. Mol Pharmacol. 2022;102(6):248–58.

[132] Huang M, et al. METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma. Cancer Res, 2023, 83(1): 89-102

[133] Xu Y, et al. Histone acetylation regulator mediated acetylation patterns define tumor malignant pathways and tumor microenvironment in hepatocellular carcinoma. Front Immunol, 2022, 13: 761046-761063

[134] Jin Q, et al. lncRNA MIR22HG-derived miR-22-5p enhances the radiosensitivity of hepatocellular carcinoma by increasing histone acetylation through the inhibition of HDAC2 activity. Front Oncol, 2021, 11

[135] Ren X, et al. Cell-cycle and apoptosis related and proteomics-based signaling pathways of human hepatoma Huh-7 cells treated by three currently used multi-RTK inhibitors. Front Pharmacol, 2022, 13

[136] Othman DIA, et al. Identification of new benzimidazole-triazole hybrids as anticancer agents: multi-target recognition, in vitro and in silico studies. J Enzyme Inhib Med Chem, 2023, 38(1): 2166037-2166053

[137] Zhou JN, et al. A Functional screening identifies a new organic selenium compound targeting cancer stem cells: Role of c-Myc transcription activity inhibition in liver cancer. Adv Sci, 2022, 9(22): e2201166-e2201181

[138] Pang Y, et al. Inhibition of abnormally activated HIF-1α-GLUT1/3-glycolysis pathway enhances the sensitivity of hepatocellular carcinoma to 5-caffeoylquinic acid and its derivatives. Eur J Pharmacol, 2022, 920

[139] Chen YY, et al. Polyphyllin D induces G2/M cell cycle arrest via dysfunction of cholesterol biosynthesis in liver cancer cells. Biomed Environ Sci, 2023, 36(1): 94-98

[140] Shi L, et al. SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers. Nat Cancer, 2023, 4(3): 365-381

[141] Li Z, Bao H. Deciphering key regulators of Inonotus hispidus petroleum ether extract involved in anti-tumor through whole transcriptome and proteome analysis in H22 tumor-bearing mice model. J Ethnopharmacol, 2022, 296

[142] Chen S, et al. Quantitative proteomics based on iTRAQ reveal that nitidine chloride induces apoptosis by activating JNK/c-Jun signaling in hepatocellular carcinoma cells. Planta Med, 2022, 88(13): 1233-1244

[143] Song J, et al. Organotin benzohydroxamate derivatives (OTBH) target colchicine-binding site exerting potent antitumor activity both in vitro and vivo revealed by quantitative proteomic analysis. Eur J Pharm Sci, 2023, 187

[144] Wang S, et al. Reactive oxygen species mediate 6c-induced mitochondrial and lysosomal dysfunction, autophagic cell death, and DNA damage in hepatocellular carcinoma. Int J Mol Sci, 2021, 22(20): 10987

[145] Goyal L, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med, 2023, 388(3): 228-239

[146] Azmy EM, et al. Development of pyrolo[2,3-c]pyrazole, pyrolo[2,3-d]pyrimidine and their bioisosteres as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological evaluation and molecular dynamics investigations. Bioorg Chem, 2023, 139: 106729-106744

[147] Cai LY, et al. Targeting p300/CBP attenuates hepatocellular carcinoma progression through epigenetic regulation of metabolism. Cancer Res, 2021, 81(4): 860-872

[148] Sun L, et al. Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth. Cell Chem Biol, 2022, 29(3): 373-385

[149] Pu Y, et al. CDK inhibition reverses acquired 5-fluorouracil resistance in hepatocellular carcinoma cells. Dis Markers, 2022, 2022: 6907057

[150] Gao X, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): A multicentre, open-label, phase 1b/2 trial. Lancet Oncol, 2023, 24(10): 1134-1146

[151] Wang K, et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nat Med, 2024, 30(3): 708-715

[152] Carrasco-Reinado R, et al. Development of new antiproliferative compound against human tumor vells from the marine microalgae nannochloropsis gaditana by applied proteomics. Int J Mol Sci, 2020, 22(1): 96

[153] Hou X, et al. Extracellular microparticles derived from hepatic progenitor cells deliver a death signal to hepatoma-initiating cells. J Nanobiotechnology, 2022, 20(1): 79-95

[154] Zhu D, et al. Tubulin-binding peptide RR-171 derived from human umbilical cord serum displays antitumor activity against hepatocellular carcinoma via inducing apoptosis and activating the NF-kappa B pathway. Cell Prolif, 2022, 55(5): e13241-e13260

[155] Ruenchit P, et al. Peptide of trichinella spiralis infective larval extract that harnesses growth of human hepatoma cells. Front Cell Infect Microbiol, 2022, 12

[156] Bottoni P, et al. Mitochondrial respiratory complexes as targets of drugs: The PPAR Agonist Example. Cells, 2022, 11(7): 1169

[157] Alfwuaires M, et al. Acacetin inhibits cell proliferation and induces apoptosis in human hepatocellular carcinoma cell lines. Molecules, 2022, 27(17): 5361

[158] Wang J, et al. Integrative transcriptomic and proteomics profiling analyses reveals PLK1 as a target of curcumol in hepatocellular carcinoma cells. J Funct Foods, 2023, 110: 105834-105847

[159] Gao J, et al. Component identification of phenolic acids in cell suspension cultures of Saussureainvolucrata and its mechanism of anti-hepatoma revealed by TMT quantitative proteomics. Foods, 2021, 10(10): 2466

[160] Huang R, et al. Bruceine D inhibits HIF-1α-mediated glucose metabolism in hepatocellular carcinoma by blocking ICAT/β-catenin interaction. Acta Pharm Sin B, 2021, 11(11): 3481-3492

[161] Yang L, et al. Antiproliferative activity of berberine in HepG2 cells via inducing apoptosis and arresting cell cycle. Food Funct, 2021, 12(23): 12115-12126

[162] Tang FF, et al. Network pharmacological analysis of corosolic acid reveals P4HA2 inhibits hepatocellular carcinoma progression. BMC Complement Med Ther, 2023, 23(1): 171-184

[163] Chu Z, et al. COE inhibits vasculogenic mimicry by targeting EphA2 in hepatocellular carcinoma, a research based on proteomics analysis. Front Pharmacol, 2021, 12: 619732-618745

[164] Lin J, et al. Pien Tze Huang regulates phosphorylation of metabolic enzymes in mice of hepatocellular carcinoma. Sci Rep, 2023, 13(1): 1897

[165] Li QZ, et al. Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest. Phytomedicine, 2024, 126

[166] Yao J, et al. CDK9 inhibition blocks the initiation of PINK1PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma. Autophagy, 2022, 18(8): 1879-1897

[167] Sun ST, et al. A new strategy for the rapid identification and validation of direct toxicity targets of psoralen-induced hepatotoxicity. Toxicol Lett, 2022, 363: 11-26

[168] Husain H, et al. Proteomic and molecular evidences of Il1rl2, Ric8a, Krt18 and Hsp90b1 modulation during experimental hepatic fibrosis and pomegranate supplementation. Int J Biol Macromol, 2021, 185: 696-707

[169] Zhang SN, et al. Integrated omics and bioinformatics analyses for the toxic mechanism and material basis of Sophorae Tonkinensis radix et rhizome-induced hepatotoxicity. J Pharm Biomed Anal, 2021, 198

[170] An P, et al. Synergistic antitumor effects of compound-composed optimal formula from Aidi injection on hepatocellular carcinoma and colorectal cancer. Phytomedicine, 2022, 103

[171] Ku WC, et al. Kaempferitrin-treated HepG2 differentially expressed exosomal markers and affect extracellular vesicle sizes in the secretome. Biomolecules, 2021, 11(2): 187

[172] Begolli R, et al. Transcriptome and proteome analysis reveals the anti-cancer properties of Hypnea musciformis marine macroalga extract in liver and intestinal cancer cells. Hum Genomics, 2023, 17(1): 71

[173] Jiang WM, Zhou SY. Extraction, structure characterization and biological activity of polysaccharide from coconut peel. China Food Additives, 2023, 34(5): 111-118

[174] Jiang J, et al. Advances and prospects in integrated nano-oncology. Nano Biomed Eng, 2024, 16(2): 152-187

[175] Chen W, et al. Preparation of liposomes coated superparamagnetic iron oxide nanoparticles for targeting and imaging brain glioma. Nano Biomed Eng, 2022, 14(1): 71-80

[176] Wu Y, et al. Nanomaterials for targeting liver disease: Research progress and future perspectives. Nano Biomed Eng, 2023, 15(2): 199-224

[177] Zhao L, et al. Lanthanide europium MOF nanocomposite as the theranostic nanoplatform for microwave thermo-chemotherapy and fluorescence imaging. J Nanobiotechnology, 2022, 20(1): 133

[178] Chen X, et al. A DNA/DMXAA/metal-organic framework activator of innate immunity for boosting anticancer immunity. Adv Mater, 2023, 35(15):

[179] Li J, et al. Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure. Life Sci, 2024, 342

[180] Jin ZC, et al. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): A propensity score matching study. Eur Radiol, 2023, 33(12): 8669-8681

[181] Zhu HD, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther, 2023, 8(1): 58

[182] Huang JX, et al. A Study on overcoming post-TACE drug resistance in HCC based on controllable oxygen release-magnetic hyperthermia therapy. Adv Healthc Mater. 2024:e2402253. https://doi.org/10.1002/adhm.202402253.

[183] Xia Y, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer, 2022, 10(4):

[184] Zhang D, et al. Mitochondrial TSPO promotes hepatocellular carcinoma progression through ferroptosis inhibition and immune evasion. Adv Sci, 2023, 10(15):

[185] Qin S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet, 2023, 402(10408): 1133-1146

[186] Kelley RK, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol, 2022, 23(8): 995-1008

[187] Kim HD, et al. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nat Med, 2024, 30(3): 699-707

[188] Li Y, et al. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. J Exp Clin Cancer Res, 2023, 42(1): 6

[189] Zuo B, et al. Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses. J Hematol Oncol, 2022, 15(1): 46

[190] Wang Y, et al. CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment. Bioact Mater, 2022, 17: 147-161

[191] Li B, et al. Rhamnetin decelerates the elimination and enhances the antitumor effect of the molecular-targeting agent sorafenib in hepatocellular carcinoma cells via the miR-148a/PXR axis. Food Funct, 2021, 12(6): 2404-2417

[192] Hu C, et al. Gut microbiota–derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC. Hepatology, 2023, 77: 48-64

[193] Wu CE, et al. WIP1 inhibition by GSK2830371 potentiates HDM201 through enhanced p53 phosphorylation and activation in liver adenocarcinoma cells. Cancers, 2021, 13(15): 3876

[194] Jeon Y, et al. Cannabidiol enhances cabozantinib-induced apoptotic cell death via phosphorylation of p53 regulated by ER stress in hepatocellular carcinoma. Cancers, 2023, 15: 3987-4000

[195] Ru J, et al. IRGM is a novel regulator of PD-L1 via promoting S6K1-mediated phosphorylation of YBX1 in hepatocellular carcinoma. Cancer Lett, 2024, 581

[196] Zhang Y, et al. FAK-mediated phosphorylation at Y464 regulates p85b nuclear translocation to promote tumorigenesis of ccRCC by repressing RB1 expression. Cell Rep, 2023, 42: 112188-112210

[197] Kim Y, et al. Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma. Drug Resist Updat, 2024, 73: 101054-101068

[198] Lu J, et al. Inhibition of BAG3 enhances the anticancer effect of shikonin in hepatocellular carcinoma. Am J Cancer Res, 2021, 11(7): 3575-3593

[199] Suzuki H, et al. Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors. Cancer Commun, 2023, 43(4): 415-434

[200] Hsiehchen D, et al. The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial. Nat Commun, 2024, 15(1): 2178